Implications of hepatitis C virus subtype 1a migration patterns for virus genetic sequencing policies in Italy

Authors: Aragri M, Balog D, Ceccherini-Silberstein F, Cento V, Cuypers L, Di Maio VC, Fabeni L, Focà A, Marascio N, Nevens F, Perno CF, Pineda-Peña AC, Schrooten Y, Torti C, Van Laethem K, Vandamme AM, Vrancken B
Publication Year: 2017
Journal: BMC Evolutionary Biology
Link: https://bmcevolbiol.biomedcentral.com/articles/10.1186/s12862-017-0913-3

In-depth phylogeographic analysis can reveal migration patterns relevant for public health planning. Here, as a model, we focused on the provenance, in the current Italian HCV subtype 1a epidemic, of the NS3 resistance-associated variant (RAV) Q80K, known to interfere with the action of NS3/4A protease inhibitor simeprevir. HCV1a migration patterns were analysed using Bayesian phylodynamic […]
Read More

Exploring resistance pathways for first-generation NS3/4A protease inhibitors boceprevir and telaprevir using Bayesian network learning

Authors: Ceccherini-Silberstein F, Cento V, Cuypers L, Di Maio VC, Libin P, Lunar MM, Nevens F, Nowé A, Poljak M, Schrooten Y, Theys K, Van Laethem K, Vandamme AM
Publication Year: 2017
Journal: Infection Genetics and Evolution
Link: https://www.sciencedirect.com/science/article/pii/S1567134817301582?via%3Dihub

Resistance-associated variants (RAVs) have been shown to influence treatment response to direct-acting antivirals (DAAs) and first generation NS3/4A protease inhibitors (PIs) in particular. Interpretation of hepatitis C virus (HCV) genotypic drug resistance remains a challenge, especially in patients who previously failed DAA therapy and need to be retreated with a second DAA based regimen. Bayesian […]
Read More

European Recommendations for the Clinical Use of HIV Drug Resistance Testing: 2011 Update.

Authors: Ceccherini-Silberstein F, De Luca A, European HIV Drug Resistance Guidelines Panel, Palmisano L, Paraskevis D, Paredes R, Poljak M, Schmit JC, Sönnerborg A, Soriano V, Walter H, Camacho RJ, Vandamme AM
Journal: AIDS Reviews
Link: https://apps.webofknowledge.com/full_record.do?product=UA&search_mode=GeneralSearch&qid=19&SID=Y2ytOr2frNCuRlReLtM&page=1&doc=1

The European HIV Drug Resistance Guidelines Panel, established to make recommendations to clinicians and virologists, felt that sufficient new information has become available to warrant an update of its recommendations, explained in both pocket guidelines and this full paper.
Read More

Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen

Authors: Alcaro S, Alteri C, Antinori A, Artese A, Beheydt G, Bertoli A, Ceccherini-Silberstein F, Costa G, d’Arminio Monforte A, Girardi E, Gori C, Orchi N, Parrotta L, Perno CF, Santoro MM, Svicher V, Theys K, Vandamme AM
Publication Year: 2013
Journal: Journal of Antimicrobial Chemotherapy
Link: http://www.ncbi.nlm.nih.gov/pubmed/23687186

This study evaluates the impact of specific HIV-1 protease-compensatory mutations (wild-type amino acids in non-B subtypes) on virological response to a first-line lopinavir/ritonavir-containing regimen in an HIV-1 subtype B-infected population.
Read More

Implications of hepatitis C virus subtype 1a migration patterns for virus genetic sequencing policies in Italy

Exploring resistance pathways for first-generation NS3/4A protease inhibitors boceprevir and telaprevir using Bayesian network learning

European Recommendations for the Clinical Use of HIV Drug Resistance Testing: 2011 Update.

Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen

About GHTM

Contacts

Map